Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 nipocalimab versus placebo in adults with generalized myasthenia gravis
2023-504152-97-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Nipocalimab with Placebo (2 arms). Primary endpoints: Average change from baseline in MG-ADL total score over Weeks 22, 23, and 24 and Percent change in total IgG levels from Day 1 to Week 8. Planned start Sep 2023; status: authorised.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-504152-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504152-97-00.